Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

Biosimilars can not only reduce patients' financial burdens, but also encourage more people to go for early diagnosis and ...

If left unchecked, the power of PBMs and their complex relationships within the American healthcare system could lead to higher drug costs and diminished returns.

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug ...

Celltrion, a major South Korean biopharmaceutical firm, on Tuesday said it aims to achieve 5 trillion won ($3.46 billion) in s ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...